ASTRAZENECA PLC
No SEC Form 4 filings for $AZN in the last 30 days.
See all $AZN insider activity →The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) for treating advanced breast cancer with ESR1 mutations. The approval was based on a clinical trial showing 16-month median progression-free survival. The FDA required confirmatory studies to verify clinical benefit. The approval includes a companion diagnostic test, Guardant360 CDx, for identifying eligible patients.
Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
AstraZeneca and Amgen reported positive phase 3 trial results for tezepelumab (Tezspire) in treating eosinophilic esophagitis (EoE). The study showed improved dysphagia and histologic remission at weeks 24 and 52 compared to placebo. The companies plan to share data with regulators. Tezspire is already FDA-approved for severe asthma and chronic rhinosinusitis.
Over the past 7 days, alphai's AI scored 24 news stories mentioning AZN (ASTRAZENECA PLC). Coverage has skewed bullish: 16 bullish, 3 neutral, and 5 bearish.
Recent AZN coverage spans technology, regulation and market movers.
Positive regulatory event likely to boost AZN share price as the drug enters market.
First‑line combo adds to oncology pipeline.
Positive trial results may boost AZN stock and pipeline valuation.
Positive trial data may boost AZN share price and expand TEZSPIRE indications.
Potential short‑term price pressure as investors assess legal risk and cost impact.
alphai scores every news story that mentions AZN with an AI model for sentiment and relevance, and aggregates insider trades from ASTRAZENECA PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) for treating advanced breast cancer with ESR1 mutations. The approval was based on a clinical trial showing 16-month median progression-free survival. The FDA required confirmatory studies to verify clinical benefit. The approval includes a companion diagnostic test, Guardant360 CDx, for identifying eligible patients.
2 min readIonis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
3 min readAstraZeneca and Amgen reported positive phase 3 trial results for tezepelumab (Tezspire) in treating eosinophilic esophagitis (EoE). The study showed improved dysphagia and histologic remission at weeks 24 and 52 compared to placebo. The companies plan to share data with regulators. Tezspire is already FDA-approved for severe asthma and chronic rhinosinusitis.
2 min readAstraZeneca and Amgen's TEZSPIRE met primary endpoints in a Phase III trial for eosinophilic esophagitis, showing significant improvements in histologic remission and dysphagia symptoms. The drug maintained efficacy through 52 weeks, with results planned for regulatory submission. TEZSPIRE is approved for severe asthma and chronic rhinosinusitis with nasal polyps.
2 min readAstraZeneca settled a $34M case with Texas over alleged improper patient support services for 17 drugs. EyePoint Pharmaceuticals settled a $4.66M case over alleged kickbacks for its eye medication DEXYCU. The FDA's PCAC recommended six peptides for inclusion on the 503A bulks list, contradicting FDA staff recommendations.
2 min readReports of a potential merger between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) caused a 5% drop in AstraZeneca's shares, wiping £17 billion off its market value. Both companies denied the reports, and analysts suggest antitrust scrutiny would be significant due to overlapping oncology businesses. The FTSE 100 traded flat, with oil prices also falling due to geopolitical developments.
2 min readDelveInsight reports the osteosarcoma market, valued at $60M in 2025, is expected to grow at a 9% CAGR through 2036. Key emerging therapies include OST-HER2 (OS Therapies), DANYELZA (SERB Pharmaceutical), and Tegavivint (Iterion Therapeutics). OST-HER2 is in Phase IIb trials, with FDA meetings planned for September 2026. The market's growth is driven by novel targeted therapies and increasing research efforts.
3 min readModerna's market value surged $45B after positive cancer vaccine data. Ultragenyx gained FDA approval for Genglycos, its first gene therapy. BioMarin acquired Alesta Therapeutics for $275M. AstraZeneca scrapped a Phase 3 lung cancer trial. Argenx reported positive Phase 3 data for Vyvgart. Capricor's CEO indicated FDA willingness to review updated cell therapy submission.
5 min readAstraZeneca (AZN) and HUTCHMED reported positive phase III SANOVO study results for Tagrisso (osimertinib) plus Orpathys (savolitinib) in treatment-naïve EGFR-mutated NSCLC with MET overexpression. The combination showed statistically significant improvement in progression-free survival (PFS) versus Tagrisso alone. AZN shares have fallen 11.7% year to date, underperforming the industry.
2 min readAstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) discontinued a phase 3 trial for Wainua, a combination therapy for ATTR-CM. Analysts debate whether Alnylam Pharmaceuticals (ALNY) can succeed with its RNA silencing drugs in this area. ALNY's drugs are being considered for use with standard TTR stabilizers, targeting the disease through different pathways. The outcome may impact the ATTR-CM market and RNA therapeutics sector.
2 min read
